Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 24:13:996663.
doi: 10.3389/fimmu.2022.996663. eCollection 2022.

Cancer immunotherapy strategies that target the cGAS-STING pathway

Zhuoying Tian  1   2 , Yue Zeng  1 , Yurong Peng  1 , Junqi Liu  1 , Fang Wu  1   3   4   5
Affiliations
Review

Cancer immunotherapy strategies that target the cGAS-STING pathway

Zhuoying Tian et al. Front Immunol. .

Abstract

Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges.

Keywords: STING; cGAS; cancer-immunity cycle; immunotherapy; tumor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The cGAS-STING pathway regulates each step of the cancer-immunity cycle. Combination therapy of STING agonists can target different steps of the cancer-immunity cycle and contribute to solving immunotherapy challenges in the corresponding immune types of tumors. APC, antigen-presenting cell; PD-L1, programmed death-ligand 1; DDR, DNA damage response; VEGF, vascular endothelial growth factor; IDO, indoleamine 2,3-dioxygenase; ICIs, immune checkpoint inhibitors; CAR-T cell, chimeric antigen receptor-T cell. By Figdraw.
See this image and copyright information in PMC

References

    1. Bai J, Liu F. Nuclear cGAS: sequestration and beyond. Protein Cell (2021) 13(2):90–101. doi: 10.1007/s13238-021-00869-0 - DOI - PMC - PubMed
    1. Bai J, Liu F. cGAS−STING signaling and function in metabolism and kidney diseases. J Mol Cell Biol (2021) 13:728–38. doi: 10.1093/jmcb/mjab066 - DOI - PMC - PubMed
    1. Bai J, Liu F. The cGAS-cGAMP-STING pathway: A molecular link between immunity and metabolism. Diabetes (2019) 68:1099–108. doi: 10.2337/dbi18-0052 - DOI - PMC - PubMed
    1. Bai J, Cervantes C, He S, He J, Plasko GR, Wen J, et al. Mitochondrial stress-activated cGAS-STING pathway inhibits thermogenic program and contributes to overnutrition-induced obesity in mice. Commun Biol (2020) 3:257. doi: 10.1038/s42003-020-0986-1 - DOI - PMC - PubMed
    1. Bai J, Cervantes C, Liu J, He S, Zhou H, Zhang B, et al. DsbA-l prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway. Proc Natl Acad Sci U.S.A. (2017) 114(46):12196–201. doi: 10.1073/pnas.1708744114 - DOI - PMC - PubMed

Publication types